- A nationwide nested case-control study in Denmark analyzed data from 2.26 million participants to examine the association between cumulative use of anticholinergic bladder drugs and the risk of all-cause dementia.
- The primary analysis compared the use of anticholinergic bladder drugs with nonuse, while the secondary analysis used the beta-3 agonist mirabegron as an active comparator.
- Anticholinergic bladder drugs were associated with increased dementia risk, particularly tolterodine, solifenacin, trospium, and fesoterodine.
- No increased risk of dementia was observed when these agents were compared with mirabegron.
- The study utilized active comparators and emphasized the need for further investigation into the long-term cognitive effects of these medications.
Dementia Risk: Anticholinergic Bladder Drug Choice Key
Conexiant
February 28, 2025
